<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03928314</url>
  </required_header>
  <id_info>
    <org_study_id>101-18101</org_study_id>
    <nct_id>NCT03928314</nct_id>
  </id_info>
  <brief_title>Study of ORIC-101 in Combination With Anticancer Therapy</brief_title>
  <official_title>An Open-label Phase 1b Study of ORIC-101 in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oric Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oric Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish the recommended Phase 2 dose (RP2D), safety,&#xD;
      pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-101&#xD;
      in combination with nab-paclitaxel or other anticancer therapies when administered to&#xD;
      patients with advanced or metastatic solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ORIC-101 is a small molecule GR antagonist being developed for the treatment of patients with&#xD;
      solid tumor malignancies. Mechanistically, ORIC-101 inhibits GR transcriptional activity and&#xD;
      blocks the pro-survival signals mediated by the activated nuclear receptor.&#xD;
&#xD;
      This is an open-label, uncontrolled, multicenter, dose-finding study to assess the safety and&#xD;
      preliminary antitumor activity of ORIC-101 in combination with nab-paclitaxel or other&#xD;
      anticancer therapy in patients with advanced or metastatic solid tumors. The study will begin&#xD;
      with dose finding in combination initially with nab-paclitaxel in patients with various solid&#xD;
      tumors (Part I); additional dose expansion cohorts in specific tumor types with&#xD;
      nab-paclitaxel (Part II) or with other anticancer therapies may be evaluated through protocol&#xD;
      amendment(s).&#xD;
&#xD;
      The study will first evaluate intermittent administration (5 days on, 2 days off for 21 days)&#xD;
      of ORIC-101 followed by continuous administration (daily for 21 days) in combination with&#xD;
      nab-paclitaxel using a standard 3+3 dose escalation design.&#xD;
&#xD;
      In Part II, patients will be enrolled across four cohorts of advanced or metastatic disease:&#xD;
&#xD;
        -  pancreatic ductal adenocarcinoma (PDAC)&#xD;
&#xD;
        -  ovarian cancer&#xD;
&#xD;
        -  triple negative breast cancer (TNBC)&#xD;
&#xD;
        -  other solid tumors&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2, 2019</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Standard 3+3 dose escalation design, followed by dose expansion</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part I: Recommended Phase 2 Dose (RP2D)</measure>
    <time_frame>12 months</time_frame>
    <description>RP2D as determined by 3+3 dose escalation design</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part II: Objective Response Rate (ORR)</measure>
    <time_frame>18 months</time_frame>
    <description>Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and assessed by Blinded Independent Central Review (BICR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part I: Maximum plasma concentration (Cmax)</measure>
    <time_frame>28 Days</time_frame>
    <description>PK of ORIC-101 in combination with nab-paclitaxel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: Time of maximum observed concentration (Tmax)</measure>
    <time_frame>28 Days</time_frame>
    <description>PK of ORIC-101 in combination with nab-paclitaxel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: Area under the curve (AUC(0-t))</measure>
    <time_frame>28 Days</time_frame>
    <description>PK of ORIC-101 in combination with nab-paclitaxel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts I and II: Number of Participants with Adverse Events</measure>
    <time_frame>36 months</time_frame>
    <description>Safety and tolerability of ORIC-101 in combination with nab-paclitaxel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts I and II: Number of Participants with Abnormal Laboratory Values</measure>
    <time_frame>36 months</time_frame>
    <description>Safety and tolerability of ORIC-101 in combination with nab-paclitaxel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts I and II: Number of Participants with Abnormal 12-lead ECG</measure>
    <time_frame>36 months</time_frame>
    <description>Safety and tolerability of ORIC-101 in combination with nab-paclitaxel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts I and II: Number of Participants with Abnormal Vital Signs</measure>
    <time_frame>36 months</time_frame>
    <description>Safety and tolerability of ORIC-101 in combination with nab-paclitaxel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: Number of Participants with Antitumor Activity</measure>
    <time_frame>36 months</time_frame>
    <description>Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: Duration of Response (DOR)</measure>
    <time_frame>36 months</time_frame>
    <description>Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and assessed by Blinded Independent Central Review (BICR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: Progression-Free Survival (PFS)</measure>
    <time_frame>36 months</time_frame>
    <description>Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and assessed by Blinded Independent Central Review (BICR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: Overall Survival (OS)</measure>
    <time_frame>36 months</time_frame>
    <description>Time from first dose of ORIC-101 in combination with nab-paclitaxel to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: Investigator-assessed ORR</measure>
    <time_frame>36 months</time_frame>
    <description>Response Evaluation Criteria in Solid Tumors (RECIST) 1.1</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Parts I and II: Number of Participants with GR Expression by IHC</measure>
    <time_frame>36 months</time_frame>
    <description>Level of GR expression by IHC in tumor tissue samples</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">174</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Dose Escalation (Part I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ORIC-101 dosed orally, once per day, for 5 or 7 days/week in combination with nab-paclitaxel (75 or 100 mg/m2 on Days 1, 8, and 15) of each 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion (Part II)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RP2D dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORIC-101</intervention_name>
    <description>ORIC-101 once daily, 5 or 7 days/week, for 21 days of each 28-day cycle</description>
    <arm_group_label>Dose Escalation (Part I)</arm_group_label>
    <arm_group_label>Dose Expansion (Part II)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>75 or 100 mg/m2 Days 1, 8, and 15 of each 28-day cycle</description>
    <arm_group_label>Dose Escalation (Part I)</arm_group_label>
    <arm_group_label>Dose Expansion (Part II)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (Part I):&#xD;
&#xD;
          -  Advanced or metastatic solid tumor, with the exception of neuroendocrine tumors that&#xD;
             secrete adrenocorticotropic hormone (ACTH) or corticotropin-releasing hormone (CRH),&#xD;
             for which no alternative effective standard therapy is available or for which standard&#xD;
             therapy is considered unsuitable or intolerable&#xD;
&#xD;
          -  Measurable disease (ie, presenting with at least one measurable lesion per RECIST 1.1)&#xD;
&#xD;
          -  Radiographic evidence of a lesion that may be safely biopsied by core needle biopsy&#xD;
&#xD;
          -  For patients with treated, stable CNS metastases that are asymptomatic: no evidence of&#xD;
             progression for at least 4 weeks after CNS-directed treatment as determined by&#xD;
             clinical examination and brain imaging. Patients must not require steroids&#xD;
&#xD;
          -  ECOG performance status 0 or 1&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  Available archival FFPE tissue for submission to central laboratory&#xD;
&#xD;
          -  Male: must agree to birth control requirements and Female: not pregnant,&#xD;
             breastfeeding, and meets requirements regarding women of child-bearing potential&#xD;
&#xD;
          -  Capable of giving signed informed consent&#xD;
&#xD;
          -  Agreement and ability to undergo two on-study biopsies, as follows, through a&#xD;
             procedure that is deemed to be clinically feasible and not carry significant risk:&#xD;
&#xD;
               -  one pre-treatment tumor biopsy obtained prior to dosing; and&#xD;
&#xD;
               -  one post-treatment tumor biopsy during Cycle 2&#xD;
&#xD;
        Exclusion Criteria (Part I):&#xD;
&#xD;
          -  Any other current or active malignancy&#xD;
&#xD;
          -  Grade 2 or higher peripheral neuropathy&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Major surgery within 21 days prior to Cycle 1 Day 1 or incomplete recovery from&#xD;
             adverse effects resulting from such procedure&#xD;
&#xD;
          -  Females: history of unexplained vaginal bleeding in the 8 weeks prior to planned study&#xD;
             treatment&#xD;
&#xD;
          -  History of Cushing's syndrome or adrenal insufficiency&#xD;
&#xD;
          -  Other concurrent serious uncontrolled medical, psychological, or addictive conditions&#xD;
             that may interfere with planned study treatment or adherence to protocol&#xD;
&#xD;
          -  Prior or current treatment with ORIC-101 or any other GR antagonist (eg, mifepristone,&#xD;
             relacorilant)&#xD;
&#xD;
          -  Current or requirement for chronic use of systemic corticosteroids with the exception&#xD;
             of inhaled, topical, intraocular, intranasal, or intraarticular corticosteroids.&#xD;
&#xD;
          -  Current or expected on-study treatment with specified strong CYP3A4 inhibitors or&#xD;
             inducers&#xD;
&#xD;
          -  Treatment with another investigational medicinal product (within 3 weeks prior to&#xD;
             starting study treatment)&#xD;
&#xD;
          -  Receiving any other anticancer therapy, radiotherapy, or herbal (alternative)&#xD;
             medicines within 7 days prior to starting study treatment&#xD;
&#xD;
          -  Use of hormone replacement therapy by females&#xD;
&#xD;
          -  Current enrollment in any other therapeutic clinical study involving an&#xD;
             investigational study treatment&#xD;
&#xD;
          -  Presence of Hepatitis B surface antigen at screening&#xD;
&#xD;
          -  Positive Hepatitis C antibody test result at screening or within 3 months prior to&#xD;
             starting study treatment&#xD;
&#xD;
          -  Positive Hepatitis C RNA test result at screening or within 3 months prior to first&#xD;
             dose of study treatment&#xD;
&#xD;
          -  Unacceptable laboratory criteria:&#xD;
&#xD;
               -  ANC &lt;1500 cells/mm3 (1.5 × 103 cells/mm3)&#xD;
&#xD;
               -  Platelets &lt;100,000 /µL (100 × 109 /L)&#xD;
&#xD;
               -  Hemoglobin &lt;9.0 g/dL (90 g/L)&#xD;
&#xD;
               -  Albumin &lt;3.0 g/dL (30 g/L)&#xD;
&#xD;
               -  AST (SGOT) or ALT(SGPT) &gt;2.5 × ULN&#xD;
&#xD;
               -  AST (SGOT) or ALT (SGPT) &gt;2.5 and ≤5.0 × ULN is acceptable for patients with&#xD;
                  liver metastases&#xD;
&#xD;
          -  Bilirubin &gt;1.5 × ULN:&#xD;
&#xD;
               -  Isolated bilirubin &gt;1.5 × ULN is acceptable if bilirubin is fractionated and&#xD;
                  direct bilirubin &lt;35% of total bilirubin&#xD;
&#xD;
               -  Bilirubin &gt;1.5 and ≤3.0 × ULN is acceptable for patients with known Gilbert's&#xD;
                  disease&#xD;
&#xD;
          -  QTcF &gt;450 msec for males; QTcF &gt;470 msec for females; or QTcF &gt;480 msec for those with&#xD;
             bundle branch block (BBB)&#xD;
&#xD;
          -  Consumption of Seville oranges, grapefruit or grapefruit juice, pomelos, exotic citrus&#xD;
             fruits, grapefruit hybrids, or fruit juices containing these fruits from 10 days&#xD;
             before the start of study treatment&#xD;
&#xD;
          -  Sensitivity to any of the study treatments, or components thereof, or drug or other&#xD;
             allergy that, in the opinion of the investigator, contraindicates participation in the&#xD;
             study.&#xD;
&#xD;
          -  Any other condition or circumstance (eg, familial, sociological, inability to swallow&#xD;
             oral study drug) that, in the opinion of the investigator, may interfere with protocol&#xD;
             compliance or contraindicates participation in the study.&#xD;
&#xD;
        Expansion Cohorts Part II Inclusion Criteria:&#xD;
&#xD;
          -  PDAC: Advanced or metastatic PDAC previously treated with and progressed on a&#xD;
             fluoropyrimidine-based regimen and a taxane-containing chemotherapy regimen (eg,&#xD;
             gemcitabine + nab-paclitaxel). Pancreatic neuroendocrine tumors, lymphoma of the&#xD;
             pancreas, acinar pancreatic cancer, or ampullary cancer are not eligible.&#xD;
&#xD;
          -  Ovarian Cancer: Advanced or metastatic high grade serous or endometrioid epithelial&#xD;
             ovarian, primary peritoneal, fallopian tube cancer or ovarian carcinosarcoma,&#xD;
             previously treated with and progressed on a taxane-containing chemotherapy regimen;&#xD;
             clear cell, mucinous and borderline histologic subtypes are not eligible; must have&#xD;
             received at least one line of therapy with evidence of cancer progression within 6&#xD;
             months after the last dose of platinum-based therapy (ie, having a platinum-free&#xD;
             interval of &lt;6 months [platinum resistant]), or progressive disease during or&#xD;
             immediately after primary platinum-therapy, (ie, platinum refractory).&#xD;
&#xD;
          -  TNBC: Advanced or metastatic ER-negative, PR-negative, HER2-negative primary breast&#xD;
             cancer previously treated and progressed on a taxane-based chemotherapy regimen; no&#xD;
             previous or synchronous second breast cancer, unless also confirmed ER-, PR- and&#xD;
             HER2-negative; must have received at least one line of therapy in the metastatic&#xD;
             setting.&#xD;
&#xD;
          -  Other Solid Tumor: Other advanced or metastatic solid tumor previously treated with&#xD;
             and progressed on a taxane-based chemotherapy regimen, with the exception of&#xD;
             metastatic colorectal cancer, primary brain tumors, and neuroendocrine tumors that&#xD;
             secrete ACTH or CRH; must have received no more than 4 prior lines of cytotoxic or&#xD;
             myelosuppressive therapy&#xD;
&#xD;
        Other Key Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  ECOG performance status 0 or 1&#xD;
&#xD;
          -  Measurable disease as assessed centrally using RECIST 1.1&#xD;
&#xD;
          -  Treated, stable CNS metastases must be asymptomatic and must not require steroids&#xD;
&#xD;
          -  Agreement and ability to undergo two on-study biopsies, one pre-treatment obtained&#xD;
             prior to dosing and during Cycle 2&#xD;
&#xD;
          -  Adequate organ function as defined by the following criteria:&#xD;
&#xD;
               -  ANC ≥1500 cells/mm3 (1.5 × 103 cells/mm3)&#xD;
&#xD;
               -  Platelets ≥100,000 /µL (100 × 109 /L)&#xD;
&#xD;
               -  Hemoglobin ≥9.0 g/dL (90 g/L)&#xD;
&#xD;
               -  Albumin ≥3.0 g/dL&#xD;
&#xD;
               -  AST (SGOT) or ALT (SGPT) ≤2.5 × ULN, ≤5.0 × ULN for patients with liver&#xD;
                  metastases&#xD;
&#xD;
               -  Bilirubin ≤1.5 × ULN; patients with a known history of Gilbert's syndrome and/or&#xD;
                  isolated elevations of indirect bilirubin are eligible&#xD;
&#xD;
               -  QTcF ≤480 msec&#xD;
&#xD;
          -  Ability to swallow ORIC-101 intact without chewing or crushing the capsules or tablets&#xD;
&#xD;
          -  Adequate gastrointestinal absorption. If the patient has undergone gastric bypass&#xD;
             surgery and/or surgery of gastrointestinal or hepatobiliary tract, the patient must&#xD;
             demonstrate adequate absorption as evidenced by albumin ≥3.0 g/dL, controlled&#xD;
             pancreatic insufficiency (if present), and lack of evidence of malabsorption&#xD;
&#xD;
        Expansion Cohorts Part II Exclusion Criteria:&#xD;
&#xD;
          -  Any other current or active malignancy&#xD;
&#xD;
          -  Prior or current treatment with ORIC-101 or any other GR antagonist (eg, mifepristone,&#xD;
             relacorilant)&#xD;
&#xD;
          -  Concurrent treatment with any other anticancer therapy including chemotherapy,&#xD;
             hormonal therapy, immunotherapy, radiotherapy, chemoembolization, targeted therapy, or&#xD;
             an investigational agent within 28 days prior to Cycle 1 Day 1&#xD;
&#xD;
          -  Major surgery or radiotherapy within 21 days prior to Cycle 1 Day 1 or incomplete&#xD;
             recovery from adverse effects resulting from such procedures; palliative radiotherapy&#xD;
             within 1 week of Cycle 1 Day 1&#xD;
&#xD;
          -  Systemic, inhaled, or prescription strength topical corticosteroids within 21 days&#xD;
             prior to Cycle 1 Day 1; short courses (≤5 days) for non-cancer-related reasons are&#xD;
             allowed if clinically required&#xD;
&#xD;
          -  Grade 2 (moderate) or higher peripheral neuropathy per CTCAE v5.0; patients with mild&#xD;
             peripheral neuropathy may be eligible at the discretion of the investigator in&#xD;
             consultation with ORIC&#xD;
&#xD;
          -  All other toxicities from prior therapy (except alopecia) that have not resolved to&#xD;
             National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)&#xD;
             v5.0 ≤ Grade 1&#xD;
&#xD;
          -  Females: history of unexplained vaginal bleeding in the 8 weeks prior to Cycle 1 Day 1&#xD;
             (given potential for ORIC-101 to exacerbate such bleeding)&#xD;
&#xD;
          -  Females: use of hormone replacement therapy; hormone replacement therapy must be&#xD;
             discontinued to allow for confirmation of postmenopausal status&#xD;
&#xD;
          -  History of Cushing's syndrome or adrenal insufficiency&#xD;
&#xD;
          -  Current (within 10 days prior to Cycle 1 Day 1) or expected on-study treatment with&#xD;
             specified strong CYP3A4 inhibitors or inducers&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) infection, unless patient is healthy and has&#xD;
             a low risk of AIDS-related outcomes&#xD;
&#xD;
          -  Presence of Hepatitis B surface antigen (HBsAg) at screening&#xD;
&#xD;
          -  Positive Hepatitis C (HCVAb) antibody test result at screening or within 3 months&#xD;
             prior to Cycle 1 Day 1. NOTE: Patients with positive HCVAb due to prior resolved&#xD;
             disease can be enrolled if a confirmatory negative Hepatitis C RNA test is obtained&#xD;
&#xD;
          -  Positive Hepatitis C RNA test result at screening or within 3 months prior to Cycle 1&#xD;
             Day 1. NOTE: Test is optional and patients with negative HCVAb test are not required&#xD;
             to also undergo Hepatitis C RNA testing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pratik S. Multani, MD</last_name>
    <role>Study Director</role>
    <affiliation>Oric Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maureen Duff, PharmD</last_name>
    <phone>650-388-5600</phone>
    <email>maureen.duff@oricpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Edna Chow Maneval, PhD</last_name>
    <phone>650-388-5600</phone>
    <email>edna.chowmaneval@oricpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford Cancer Institute</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aja Macias</last_name>
      <phone>650-721-4090</phone>
      <email>amacias2@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shabana Akramy</last_name>
      <phone>415-514-6674</phone>
      <email>shabana.akramy@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Pamela Munster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado - PPDS</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meghan Ayers</last_name>
      <phone>303-724-8681</phone>
      <email>Meghan.ayers@cuanschutz.edu</email>
    </contact>
    <investigator>
      <last_name>Sarah Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute</name>
      <address>
        <city>Lake Mary</city>
        <state>Florida</state>
        <zip>32746</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Keville</last_name>
      <phone>407-804-6133</phone>
      <email>jessica.keville@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Shekeab Jauhari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Williams</last_name>
      <phone>941-377-9993</phone>
      <email>hmwilliams@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Manish Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Moher</last_name>
      <phone>503-418-9324</phone>
      <email>moher@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Shivaani Kummar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology NASH - SCRI - PPDS</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ethan Trull</last_name>
      <phone>615-329-7274</phone>
      <email>Ethan.Trull@SarahCannon.com</email>
    </contact>
    <investigator>
      <last_name>Erika Hamilton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Centers - Medical City</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ned Adams</last_name>
      <phone>214-739-4175</phone>
      <email>nadams@marycrowley.org</email>
    </contact>
    <investigator>
      <last_name>James Strauss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenn Childress</last_name>
      <phone>713-792-2121</phone>
      <email>jachildress@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Naoto Ueno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique McReynolds</last_name>
      <phone>210-580-9516</phone>
      <email>dmcreynolds@nextoncology.com</email>
    </contact>
    <investigator>
      <last_name>David Sommerhalder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah - Huntsman Cancer Institute - PPDS</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hunfa Asghar</last_name>
      <phone>801-585-0255</phone>
      <email>hunfa.asghar@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Vaia Florou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Hackmaster</last_name>
      <phone>703-208-9280</phone>
      <email>melissa.hackmaster@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Alex Spira, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 19, 2019</study_first_submitted>
  <study_first_submitted_qc>April 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2019</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GR antagonist</keyword>
  <keyword>Glucocorticoid receptor antagonist</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

